AKT1 E17K Inhibitor ATV-1601

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally bioavailable non-covalent allosteric inhibitor of the serine/threonine protein kinase AKT (protein kinase B; v-akt murine thymoma viral oncogene homolog 1) isoform 1 mutation AKT1 E17K, with potential antineoplastic activity. Upon oral administration, AKT1 E17K inhibitor ATV-1601 targets, allosterically binds to and inhibits AKT1 E17K. This may inhibit growth of and induce apoptosis in AKT1 E17K-driven cancers. AKT1 E17K, overexpressed in a variety of cancer cell types, drives cancer cell proliferation. By specifically targeting the E17K mutant variant, ATV-1601 may avoid the toxicities associated with wild-type (WT) AKT inhibition.

**Synonyms:** - AKT1 E17K-mutant Inhibitor ATV-1601 - ATV 1601 - ATV-1601 - ATV1601 - Mutant-selective AKT1 Inhibitor ATV-1601